Emergency approval of coronavirus vaccines is not guaranteed, FDA commissioner says

Emergency approval of coronavirus vaccines is not guaranteed, FDA commissioner says

Career scientists at the FDA are reviewing raw data from the Pfizer and Moderna trials for the first time, investigating any adverse events or side effects that transpired over the course of the trials, different levels of effectiveness among populations and age groups, and whether individuals who were already infected by the coronavirus might have had any unexpected reactions to the vaccine doses.

Hahn said they will also be looking for evidence that the vaccines lead to increased respiratory infections – a concern with vaccines produced for other coronaviruses, such as SARS and MERS – and whether the use of a relatively new method of vaccine development, known as messenger RNA technology, poses any significant risks.

‘Fatigued’ Trump Given Experimental COVID-19 Drug: White House Doc

‘Fatigued’ Trump Given Experimental COVID-19 Drug: White House Doc

Trump received a single eight gram dose of Regeneron’s polyclonal antibody cocktail “as a precautionary measure,” Conley said in a Friday afternoon memo. He’s also been taking zinc, vitamin D, famotidine, melatonin and daily aspirin.

Regeneron’s antibody cocktail doesn’t have FDA approval but has emergency approval and near the end of its Phase 3 trials. It has been found to reduce the viral load and improve symptoms in non-hospitalized COVID-19 patients.

Related:

President Trump going to Walter Reed after COVID-19 diagnosis

Abbott soars 10% after its 15-minute COVID-19 test wins FDA approval (ABT)

Abbott soars 10% after its 15-minute COVID-19 test wins FDA approval (ABT)

The new COVID test will be accompanied by a free smartphone app that will display a user’s test results, which can then be displayed when asked at social gathering places like schools and workplaces.

Related:

FDA gives emergency-use approval for Abbott’s $5, 15-minute COVID-19 test, though not for home use

The test should help meet a growing demand for cheap, less-accurate COVID-19 tests that some public health officials argue the U.S. needs to return to school and work. Peter Weber